Press releases
- Bausch + Lomb Will Release Second-Quarter 2024 Financial Results on July 31
- Millions of Americans Experience Dry Eye Symptoms, Yet New National Survey Shows Sufferers Struggle to Find Relief
- Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress
- Bausch + Lomb INFUSE® for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States
- Bausch + Lomb Launches Blink™ NutriTears® Clinically Proven Nutritional Supplement for Dry Eyes in the United States
- Bausch + Lomb Announces 2024 Annual Meeting of Shareholder Results
- Bausch + Lomb Announces Presentation of New Scientific Data and Evaluations Featuring Consumer, Vision Care and Pharmaceutical Products at Optometry’s Meeting®
- Bausch + Lomb Receives Health Canada Approval for enVista® Envy™* Full Visual Range Intraocular Lens
- Bausch + Lomb Announces First-Quarter 2024 Results
- Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting
More ▼
Key statistics
On Monday, Bausch + Lomb Corp (BLCO:NYQ) closed at 17.30, -15.28% below its 52-week high of 20.42, set on Jul 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.30 |
---|---|
High | 17.32 |
Low | 16.95 |
Bid | 15.91 |
Offer | 17.00 |
Previous close | 16.98 |
Average volume | 514.95k |
---|---|
Shares outstanding | 351.83m |
Free float | 40.46m |
P/E (TTM) | -- |
Market cap | 5.89bn USD |
EPS (TTM) | -0.9603 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 23:30 BST.
More ▼